ORGANOGENESIS HOLDINGS INC. Payments of Stock Issuance Costs
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Payments of Stock Issuance Costs of $5.66 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-01
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for the quarter ending 2018-12-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for the quarter ending 2017-09-30 was $0.00.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for the quarter ending 2017-06-30 was $0.00.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for fiscal 2020 was $5.66M, a 90.25% increase from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for fiscal 2019 was $2.97M, a 1001.11% increase from fiscal 2018.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for fiscal 2018 was $270.00K, a 36.85% decline from fiscal 2017.
- ORGANOGENESIS HOLDINGS INC. payments of stock issuance costs for fiscal 2017 was $427.58K, a 22.60% increase from fiscal 2016.
| Period end | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $5.66M 10-K · filed 2023-03-01 | ||||
| 2019-12-31 | $2.97M 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $270.00K 10-K · filed 2021-03-16 | |||
| 2018-09-30 | $270.00K 10-Q · filed 2019-11-12 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 derived: sum of 3 quarters · filed 2018-11-09 | $427.58K 10-K · filed 2018-03-14 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $427.58K 10-Q · filed 2018-11-09 | $721.60K derived: sum of 4 quarters · filed 2018-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $427.58K 10-Q · filed 2018-08-07 | $721.60K derived: sum of 3 quarters · filed 2018-08-07 | ||
| 2017-03-31 | $427.58K 10-Q · filed 2018-05-10 | $721.60K derived: sum of 2 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $294.02K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $348.76K 10-K · filed 2018-03-14 | |||
| 2016-09-30 | $54.74K 10-Q · filed 2017-11-14 | ||||
| 2016-03-31 | $20.00K 10-Q · filed 2017-05-12 | ||||
| 2015-12-31 | $57.25K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |